Volanesorsen (Waylivra), the antisense oligonucleotide (ASO) targeting apolipoprotein C-III mRNA, gets a hearing before the FDA Thursday when the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meets to review the new drug application submitted by sponsor Akcea Therapeutics Inc. The therapy has been advanced as an adjunct to diet to treat individuals with familial chylomicronemia syndrome (FCS), a rare genetic disease characterized by the build-up of chylomicrons, the largest lipoprotein particle, responsible for transporting dietary fat and cholesterol. FCS is characterized by extremely high triglycerides (TGs), putting patients at risk for multiple complications, including recurrent, potentially fatal bouts of pancreatitis.